Market Overview

The Global Breast Cancer Liquid Biopsy Market was valued at USD 424.7 million in 2023 and is expected to reach USD 2,420.4 million by 2031 while growing at a CAGR of 24.3% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global breast cancer liquid biopsy market growth. Liquid biopsies have shown promising outcomes in breast cancer, particularly in monitoring treatment response and forecasting disease progression or relapse. With ongoing research and anticipated advancements in technologies for isolating tumor-derived materials, liquid biopsies have the potential to assume a more significant role in breast cancer clinics.

Continuous advancements in liquid biopsy technologies, including enhancements in sensitivity, specificity, and the discovery of novel biomarkers, elevate the precision and dependability of these tests, while the increasing incidence of breast cancer propels market expansion. Nonetheless, challenges related to sensitivity and specificity, along with limited clinical validation, serve as impediments to market growth.

Furthermore, the global breast cancer liquid biopsy industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Biomarkers Analysis

The Global Breast Cancer Liquid Biopsy Market is segmented among Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers, based on Biomarkers. In 2023, Circulating Cell-free DNA (cfDNA) accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Application Analysis

The Global Breast Cancer Liquid Biopsy Market is segmented among Early Detection/Screening, Diagnosis, Treatment Selection, and Monitoring, based on Application. In 2023, Treatment Selection accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Breast Cancer Liquid Biopsy Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Janssen Diagnostics, Biocept Inc., Guardant Health Inc., Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, and Illumina Inc.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Breast Cancer Liquid Biopsy Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Breast Cancer Liquid Biopsy Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Breast Cancer Liquid Biopsy Market Segmentation, By Biomarkers

• Global Breast Cancer Liquid Biopsy Market Share Analysis, By Biomarkers

• Global Breast Cancer Liquid Biopsy Market Growth Analysis, By Biomarkers

• Global Breast Cancer Liquid Biopsy Market Trends, By Biomarkers

o Circulating Tumor Cells (CTCs)

o Circulating Cell-free DNA (cfDNA)

o Extracellular Vesicles (EVs)

o Other Circulating Biomarkers

6. Global Breast Cancer Liquid Biopsy Market Segmentation, By Application

• Global Breast Cancer Liquid Biopsy Market Share Analysis, By Application

• Global Breast Cancer Liquid Biopsy Market Growth Analysis, By Application

• Global Breast Cancer Liquid Biopsy Market Trends, By Application

o Early Detection/Screening

o Diagnosis

o Treatment Selection

o Monitoring

7. Global Breast Cancer Liquid Biopsy Market Segmentation, By Region

• Global Breast Cancer Liquid Biopsy Market Share Analysis, By Region

• Global Breast Cancer Liquid Biopsy Market Growth Analysis, By Region

• Global Breast Cancer Liquid Biopsy Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

8. Competitive Landscape

• Qiagen*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• F. Hoffmann-La Roche Ltd

• Bio-Rad Laboratories Inc.

• Janssen Diagnostics

• Biocept Inc.

• Guardant Health Inc.

• Myriad Genetics

• Adaptive Biotechnologies

• Epic Sciences

• Illumina Inc.

*Similar analysis will be provided for each company listed above.